Pharma Business review is using cookies

ContinueLearn More
September 24, 2018

Novartis plans to file for new Lucentis indication in ROP

Novartis has unveiled plans to file ex-US for a new indication for Lucentis (ranibizumab) in retinopathy of prematurity (ROP), a rare disease in premature infants.

Image: Novartis headquarters in Basel, Switzerland. Photo: courtesy of Novartis AG.